Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement component 1q (C1q) is the initiating protein of the classical complement pathway, a vital arm of the innate immune system (UniProt P02745; Wikipedia). It is a large, 460 kDa glycoprotein complex composed of 18 polypeptide chains—six each of the A, B, and C chains—arranged in a "bouquet" structure with six globular heads. C1q acts as a pattern recognition receptor, binding to the Fc regions of IgM or IgG in immune complexes, as well as to apoptotic cells and specific pathogen surfaces. This binding triggers the activation of the C1 complex (C1q, C1r, and C1s), launching a proteolytic cascade that leads to opsonization, recruitment of inflammatory cells, and direct cell lysis. Beyond its classical immune functions, C1q plays a critical role in neurodevelopment by tagging redundant synapses for elimination by microglia, a process known as synaptic pruning. Dysregulation of C1q is linked to various pathologies: C1q deficiency or autoantibodies are strongly associated with systemic lupus erythematosus (SLE), while its aberrant activation at synapses is a driver of neurodegeneration in diseases like Alzheimer's, ALS, and glaucoma. Therapeutic agents such as ANX005 and ANX007 are designed to bind C1q and selectively inhibit the classical pathway, aiming to preserve neuronal health and mitigate autoimmune damage while leaving other complement pathways intact for host defense.
Selective inhibition of the classical complement pathway by binding to the C1q protein, preventing the activation of the C1 complex (C1r and C1s) and the subsequent downstream inflammatory and neurodegenerative cascades.
3 more in the full profile.
Source types: Peer-reviewed publication · Government or health-agency page · Other public source. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement component 1q (C1q) (C1q).